PROTEOME SCIENCES plc
28th September 2006
Stroke Licence Agreement
Proteome Sciences plc ("Proteome Sciences") is pleased to announce a research
licence agreement with a further leading global diagnostics company in order
for that company to evaluate Proteome Sciences' biomarkers for the detection,
diagnosis and monitoring of stroke. The biomarkers were discovered and
validated using a combination of different proteomic approaches available
through Proteome Sciences' proprietary ProteoSHOP® platform.
Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 million
die and another 5 million are left permanently disabled, placing a burden on
family and community.
In the United States about 750,000 people suffer a new or recurrent stroke each
year. Nearly 160,000 of these people die, making stroke the third leading cause
of death.
About 5.5 million U.S. stroke survivors are alive today, many of them with
permanent stroke-related disabilities. The estimated direct and indirect cost
of stroke for 2006 is $57.9 billion.
No financial details were disclosed.
Christopher Pearce, CEO of Proteome Sciences, said
"This is further endorsement of the important role that our stroke biomarkers
are playing to generate new breeds of diagnostic products and the power of the
ProteoSHOP® toolbox which has been successfully applied across a range of
different human diseases including cancer and neurodegeneration.
We are delighted to have signed a fourth licence in stroke with another global
diagnostics company and we look forward to seeing our biomarkers being
incorporated on their diagnostic platforms."
- Ends -
Notes to editors:
Proteome Sciences plc
Proteome Sciences, a global leader in applied proteomics, uses high sensitivity
proprietary technologies to detect differentially expressed proteins in
diseases. The protein biomarkers discovered in body fluids or tissues are
validated, developed and commercialised as diagnostic, prognostic or
therapeutic products through strategic alliances and out-licensing.
Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high
sensitivity/high throughput proteomics solutions, including traditional two
dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein
sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology
and diagnostic companies, to discover and exploit protein biomarkers.
Sensitizer® chemical mass tags have been developed separately as a series of
stand-alone reagents.
For further information please visit www.proteomics.com.
Enquiries:
Proteome Sciences plc
Dr. Ian Pike, Business Development Director
Email: ian.pike@proteomics.com
Christopher Pearce, Chief Executive Officer
Email: christopher.pearce@proteomics.com
Tel: +44 (0)1932 865065
Public Relations for Proteome Sciences
IKON Associates
Adrian Shaw
Tel: +44 (0)1483 535102
Mobile: +44 (0)797 9900733
Email: adrian@ikonassociates.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.